Effective Pharmacovigilance System Development: EFPIA-IPVG Consensus Recommendations

被引:8
|
作者
Peters, Tanja [1 ]
Soanes, Nigel [2 ]
Abbas, Maya [3 ]
Ahmad, Jabeen [4 ]
Delumeau, Jean-Christophe [5 ]
Herrero-Martinez, Esteban [6 ]
Paramananda, Melanie [7 ]
Piper, Johanna [8 ]
Smail-Aoudia, Fairouz [7 ]
van der Spuij, Willemijn [9 ]
Veizovic, Tina [10 ]
Winstanley, Gillian [11 ]
机构
[1] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[2] AstraZeneca PLC, Cambridge, England
[3] Johnson & Johnson Middle East, Beirut, Lebanon
[4] Innovate PV, London, England
[5] Bayer Pharma, Singapore, Singapore
[6] AbbVie Ltd, Maidenhead, Berks, England
[7] Pierre Fabre Medicament, Boulogne, France
[8] Roche Prod Ltd, Welwyn Garden City, Herts, England
[9] Bristol Myers Squibb, Steinhausen, Switzerland
[10] Takeda, London, England
[11] Amgen Canada Inc, Mississauga, ON, Canada
关键词
D O I
10.1007/s40264-020-01008-0
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Pharmaceutical legislation provides a legal framework to ensure the safe and effective use of medicines. This framework requires national regulatory authorities (NRAs) to establish and maintain a pharmacovigilance system (PV system) stating and enforcing the regulatory commitments that key stakeholders, including marketing authorisation holders (MAHs), are required to fulfil. In recent years, national legislative bodies and NRAs across the world have issued a significant amount of legislation and guidance enforcing the obligation to perform pharmacovigilance activities. In countries where the NRA is a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), safety management requirements are generally consistent with ICH guidelines. In a number of countries beyond this scope, requirements may deviate from internationally agreed standards, adding a substantial complexity and increasing burden on the stakeholders involved, whilst the benefit for patients' safety may not be evident. Committed to fulfilling safety-regulatory obligations in any country where a product licence is held, global pharmaceutical companies have accumulated a broad and deep experience acquired whilst meeting the expectations of a large array of diverse PV systems across the world. These range from sub-optimal frameworks, according to the World Health Organization (WHO) Global Benchmarking Tool, to highly effective resource-optimised PV systems. In order to support countries creating or further developing their PV systems, especially where infrastructure and resources are limited, the European Federation of Pharmaceutical Industries and Associations (EFPIA) International Pharmacovigilance Group (IPVG) has developed consensus recommendations consistent with harmonised standards for the development and step-wise implementation of key PV system components. These recommendations endorsed by the EFPIA membership constitute the focus of this review article.
引用
收藏
页码:17 / 28
页数:12
相关论文
共 50 条
  • [1] Effective Pharmacovigilance System Development: EFPIA-IPVG Consensus Recommendations
    Tanja Peters
    Nigel Soanes
    Maya Abbas
    Jabeen Ahmad
    Jean-Christophe Delumeau
    Esteban Herrero-Martinez
    Mélanie Paramananda
    Johanna Piper
    Fairouz Smail-Aoudia
    Willemijn van der Spuij
    Tina Veizovic
    Gillian Winstanley
    Drug Safety, 2021, 44 : 17 - 28
  • [2] The development of a pharmacovigilance system in Bahrain
    Abdulrasool, Zainab
    SAUDI PHARMACEUTICAL JOURNAL, 2022, 30 (06) : 825 - 841
  • [3] DEVELOPMENT OF RECOMMENDATIONS FOR THE EFFECTIVE FUNCTIONING OF THE GAS SYSTEM OF KALININGRAD REGION
    Nordin, Victor
    Shcherban, Paul
    MANAGEMENT SYSTEMS IN PRODUCTION ENGINEERING, 2012, 7 (03) : 31 - 33
  • [4] Development of Pharmacovigilance System in India and Paradigm of Pharmacovigilance Research: An Overview
    Singh, Preeti
    Vaishnav, Yogesh
    Verma, Shekhar
    CURRENT DRUG SAFETY, 2023, 18 (04) : 448 - 464
  • [5] RECOMMENDATIONS OF THE CONSENSUS DEVELOPMENT CONFERENCE ON DENTAL IMPLANTS
    SCHNITMAN, PA
    SHULMAN, LB
    JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 1979, 98 (03): : 373 - 377
  • [6] Design And Development of an Integral System of Pharmacovigilance
    Rodriguez, R.
    Montes, C. D.
    Marin, J. P.
    Escutia, R.
    DRUG SAFETY, 2012, 35 (10) : 937 - 938
  • [7] Development of a Clinical Focus Pharmacovigilance System
    Maza, J. A.
    Michel, P. G. K.
    Franchesca, R. H.
    Guadalupe, C. J. J.
    Ingrid, G. V.
    Daniela, M. Z.
    Susana, F. R.
    DRUG SAFETY, 2022, 45 (10) : 1165 - 1166
  • [8] Development of Pharmacovigilance Networking System in Thailand
    Jamekornkul, C.
    Suwannakaesawong, W.
    Uerchaikul, C.
    Preechathaveekid, S.
    DRUG SAFETY, 2012, 35 (10) : 935 - 935
  • [9] CONSENSUS RECOMMENDATIONS ON EFFECTIVE INSTITUTIONAL ANIMAL CARE AND USE COMMITTEES
    不详
    LABORATORY ANIMAL SCIENCE, 1987, 37 : 11 - 13
  • [10] Development of Tooth Brushing Recommendations Through Professional Consensus
    Glenny, Anne-Marie
    Walsh, Tanya
    Iwasaki, Makiko
    Kateeb, Elham
    Braga, Mariana Minatel
    Riley, Philip
    Melo, Paulo
    INTERNATIONAL DENTAL JOURNAL, 2024, 74 (03) : 526 - 535